CONFIRMATION OF
ANTI FIBROTIC THERAPEUTIC
& COLLABORATION AGREEMENT

RELEASE DATE: DECEMBER 15 2020

Moexa’s Smad3 NCE inhibitor products demonstrate anti- fibrotic properties with particular application to pulmonary fibrosis [ARDS] as relates to post SARS-CoV-2 (COVID-19) infections. Moexa has filed additional patents securing further rights for its products as anti-fibrotic therapeutics.

Moexa has prepared to advance research and accelerate product development through a collaboration agreement with the Geisel School of Medicine at Dartmouth College, in the USA. Reports on our collaboration will be provided in due course.

Moexa intends to accelerate product development and invites collaboration on research and/or product development with interested parties.

Parties interested in investments or further collaborations may contact us for more information. www.cancelex.com
info@moexa.com